FindTrial
Sign In

Evaluation of vitamin C effect on levels of urinary MCP 1 (Monocyte Chemoattractant Protein 1) in diabetic nephropathy patients.

TO STUDY THE EFFECT OF VITAMIN C ON URINARY MCP 1 (MONOCYTE CHEMOATTRACTANT PROTEIN 1) LEVELS IN DIABETIC NEPHROPATHY PATIENTS.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025437
Enrollment
40
Registered
2020-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Vitamin C: In one arm patients will receive Vitamin C 500 mg tablet twice daily Control Intervention1: Placebo tablet: In other arm patients will receive placebo tablets twice daily

Sponsors

Dr Mohammed Abid Ali
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender 2. Diagnosed as diabetic nephropathy (Biopsy proven)

Exclusion criteria

Exclusion criteria: 1. H/O Hypersensitivity to study drugs 2. eGFR 3. Uncontrolled hypertension 4. Patients who are on drugs which can affect study outcomes, for the past 3 months 5. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
1.The change in urinary MCP 1 levels at 12 weeks from the baselineTimepoint: 0 weeks and 12 weeks—

Secondary

MeasureTime frame
1. The change in eGFR at 12 weeks from the baseline 2. The change in urinary albumin levels at 12 weeks from baseline 3. Incidence of adverse events Timepoint: 0 weeks, 4 weeks, 8 weeks and 12 weeks—

Countries

India

Contacts

Public ContactDr P Usha Rani

Nizams Institute of Medical Sciences

ushapingali@yahoo.com9849574143

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026